CAPTRUST Financial Advisors
PBYI icon

CAPTRUST Financial Advisors’s Puma Biotechnology PBYI Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,500
Closed -$4K – 3440
2022
Q2 		$4K Hold
1,500
– – ﹤0.01% 4203
2022
Q1 		$4K Hold
1,500
– – ﹤0.01% 4263
2021
Q4 		$5K Sell
1,500
-114
-7% -$495 ﹤0.01% 4088
2021
Q3 		$11K Buy
1,614
+114
+8% +$854 ﹤0.01% 3553
2021
Q2 		$14K Hold
1,500
– – ﹤0.01% 3351
2021
Q1 		$15K Buy
+1,500
New +$16.8K ﹤0.01% 3200
2019
Q2 		– Sell
-1,306
Closed -$51K – 1981
2019
Q1 		$51K Buy
+1,306
New +$39.9K ﹤0.01% 901

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

CAPTRUST Financial Advisors's PBYI Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Puma Biotechnology (PBYI) in Q3 2022, closing a stake of 1,500 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in PBYI in Q1 2019 and held it in 7 quarters. The position peaked at $51K in Q1 2019. 83 funds tracked by Wall St. Rank hold PBYI as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Puma Biotechnology position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,500 Puma Biotechnology shares in Q3 2022, an estimated $4K.
  • CAPTRUST Financial Advisors first reported a position in Puma Biotechnology in Q1 2019 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Puma Biotechnology position peaked at $51K in Q1 2019.
  • 83 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.